Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Apatinib in Subjects With Impaired Renal Function
NCT04414852Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Jun 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of Rivoceranib in gastric cancer (GC) (3 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from Time 0 to Last Quantifiable Concentration and 1 more. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04414852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04414852.